Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and...
-
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after...
-
– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations,...
-
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - -...
-
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th...
-
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation...
-
– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of...
-
- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD...
-
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation...
-
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after...